ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2129

Distinct endotypes of SURF associated with clinical phenotypes, inflammatory cytokines, and treatment responses

Marci Macaraeg1, Nadine Saad2, Tiphanie Vogel3, Fatma Dedeoglu4, Kyle McBrearty4, Qin Sun5, Chunyan Liu5 and Grant Schulert5, 1University of Arizona College of Medicine, Tucson, AZ, 2University of Michigan, Ann Arbor, MI, 3Baylor College of Medicine, Houston, TX, 4Boston Children's Hospital, Boston, MA, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, Periodic Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2124–2158) Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Syndrome of Undifferentiated Recurrent Fevers (SURF) refers to patients with recurrent fevers who do not meet clinical or classification criteria for Periodic Fevers, Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA) syndrome or Hereditary Recurrent Fever syndromes (HRFs). Most studies on patients with SURF reveal heterogeneous presentations and responses to treatment. The aims of this study were to define endotype groups within SURF, and their treatment responses.

Methods: SURF was defined as at least 3 stereotypical recurrent fever episodes not fitting clinical criteria for PFAPA or HRFs. Patient data were collected from Cincinnati Children’s Hospital Medical Center (CCHMC), University of Michigan (UofM), Texas Children’s Hospital (TCH), and Boston Children’s Hospital (BCH). Cytokine analysis was performed on available samples. Patients were clustered using age and clinical characteristics by Partitioning Around Medoids (PAM), Hierarchical, and K-prototype clustering methods. Characteristics associated with treatment responses were analyzed using univariable and multivariable regression.

Results: A total of 110 patients were included (CCHMC=65, UofM=15, BCH=15, TCH=15). PAM clustering showed three main groups: group 1 (n=57) largely resembled PFAPA but with frequent abdominal pain and myalgia; group 2 (n=30) had rash and arthralgias; and group 3 (n=23) was fever predominant. Cytokine analysis of these clusters showed elevated levels of IFN- β in group 3, a group that was also more likely to have complete response to on demand steroids. Regression analyses supported that patients without musculoskeletal complaints tended to have a complete response to on demand steroids, patients without GI complaints tended to have complete response to colchicine, patients with anorexia tended to have a complete response to tonsillectomy/adenoidectomy, and that patients with headache and arthralgias tended to receive anti-IL1 treatment and have a complete response. Genetic analysis showed high enrichment for genes associated with innate immunity in Groups 1 and 2 (enrichment score 5.75 and 4.72, respectively).

Conclusion: We found three distinct groups of SURF patients: 1. PFAPA-like, 2. rash and arthralgias, and 3. fever predominant. This third group was immunologically distinct and most likely to respond to on-demand steroids. Groups 1 and 2 tended to have high enrichment scores for genes important in innate immunity. Larger prospective studies are needed to better define the groups that exist within SURF.

Supporting image 1Patient Demographics

Supporting image 2PAM Cluster Analysis of age and clinical characteristics

Supporting image 3Treatment responses per cluster


Disclosures: M. Macaraeg: None; N. Saad: None; T. Vogel: AstraZeneca, 5, moderna, 2, Pfizer, 2, SOBI, 1, 2, takeda, 6; F. Dedeoglu: Sobi, 6, UptoDate, 9; K. McBrearty: None; Q. Sun: None; C. Liu: None; G. Schulert: IpiNovoyx, 5, Novartis, 2, SOBI, 2.

To cite this abstract in AMA style:

Macaraeg M, Saad N, Vogel T, Dedeoglu F, McBrearty K, Sun Q, Liu C, Schulert G. Distinct endotypes of SURF associated with clinical phenotypes, inflammatory cytokines, and treatment responses [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/distinct-endotypes-of-surf-associated-with-clinical-phenotypes-inflammatory-cytokines-and-treatment-responses/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-endotypes-of-surf-associated-with-clinical-phenotypes-inflammatory-cytokines-and-treatment-responses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology